Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;6(12):1971-1972.
doi: 10.1001/jamaoncol.2020.4749.

Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer

Robert S Copeland-Halperin  1 , Mohammed Al-Sadawi  2 , Sujata Patil  3   4 , Jennifer E Liu  1   4 , Richard M Steingart  1   4 , Chau T Dang  1   4 , Anthony F Yu  1   4
Affiliations

Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer

Robert S Copeland-Halperin et al. JAMA Oncol. .

Abstract

This cohort study evaluates the association of early trastuzumab interruption with clinical outcomes in patients with ERBB2-positive breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Yu reported personal fees from Glenmark and Genentech. Dr Liu reported personal fees from Bay Labs. Dr Dang reported research funding and personal fees from Genentech/Roche and Puma Technology. Dr Steingart reported personal fees from Pfizer and Celgene. No other disclosures were reported.

Figures

Figure.
Figure.. Kaplan-Meier Plot of Recurrence-Free Survival According to Continuous vs Interrupted Trastuzumab
Recurrence-free survival was assessed in a landmark analysis from 12 months after the start date of trastuzumab for the continuous and interrupted groups. The median cumulative dose of trastuzumab received was 108 (interquartile range [IQR], 104-110) mg/kg in the continuous group and 81 (IQR, 44-98) mg/kg in the interrupted group.
See this image and copyright information in PMC

References

    1. Slamon D, Eiermann W, Robert N, et al. ; Breast Cancer International Research Group . Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283. doi:10.1056/NEJMoa0910383 - DOI - PMC - PubMed
    1. Yu AF, Yadav NU, Lung BY, et al. . Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat. 2015;149(2):489-495. doi:10.1007/s10549-014-3253-7 - DOI - PMC - PubMed
    1. Earl HM, Hiller L, Vallier AL, et al. ; PERSEPHONE Steering Committee and Trial Investigators . 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393(10191):2599-2612. doi:10.1016/S0140-6736(19)30650-6 - DOI - PMC - PubMed
    1. Pivot X, Romieu G, Debled M, et al. ; PHARE trial investigators . 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet. 2019;393(10191):2591-2598. doi:10.1016/S0140-6736(19)30653-1 - DOI - PubMed
    1. Lynce F, Barac A, Geng X, et al. . Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175(3):595-603. doi:10.1007/s10549-019-05191-2 - DOI - PMC - PubMed